CN102120051B - Hirudin anticoagulation tube sealing device for venous retention needle - Google Patents
Hirudin anticoagulation tube sealing device for venous retention needle Download PDFInfo
- Publication number
- CN102120051B CN102120051B CN2011100272229A CN201110027222A CN102120051B CN 102120051 B CN102120051 B CN 102120051B CN 2011100272229 A CN2011100272229 A CN 2011100272229A CN 201110027222 A CN201110027222 A CN 201110027222A CN 102120051 B CN102120051 B CN 102120051B
- Authority
- CN
- China
- Prior art keywords
- pipe
- tube
- sealing
- liquid storage
- hirudin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000007789 sealing Methods 0.000 title claims abstract description 148
- 108010007267 Hirudins Proteins 0.000 title claims abstract description 68
- 102000007625 Hirudins Human genes 0.000 title claims abstract description 68
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 title claims abstract description 68
- 229940006607 hirudin Drugs 0.000 title claims abstract description 68
- 230000010100 anticoagulation Effects 0.000 title abstract description 7
- 230000014759 maintenance of location Effects 0.000 title abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 91
- 210000004369 blood Anatomy 0.000 claims abstract description 57
- 239000008280 blood Substances 0.000 claims abstract description 57
- 238000001802 infusion Methods 0.000 claims description 53
- 239000003146 anticoagulant agent Substances 0.000 claims description 36
- 229940127219 anticoagulant drug Drugs 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 16
- 239000003085 diluting agent Substances 0.000 claims description 14
- 229920003023 plastic Polymers 0.000 claims description 14
- 239000004033 plastic Substances 0.000 claims description 14
- 238000010241 blood sampling Methods 0.000 claims description 10
- 238000001990 intravenous administration Methods 0.000 claims description 9
- 238000004891 communication Methods 0.000 claims description 8
- 230000000149 penetrating effect Effects 0.000 claims description 8
- 229920005549 butyl rubber Polymers 0.000 claims description 7
- 239000012567 medical material Substances 0.000 claims description 7
- 229920000573 polyethylene Polymers 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- 229920002620 polyvinyl fluoride Polymers 0.000 claims description 7
- 229910001220 stainless steel Inorganic materials 0.000 claims description 7
- 239000010935 stainless steel Substances 0.000 claims description 7
- 238000003780 insertion Methods 0.000 claims description 6
- 230000037431 insertion Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 13
- 238000012360 testing method Methods 0.000 abstract description 8
- 210000002966 serum Anatomy 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 108090000190 Thrombin Proteins 0.000 description 13
- 229960004072 thrombin Drugs 0.000 description 12
- 229920000669 heparin Polymers 0.000 description 11
- 241000237903 Hirudo Species 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 8
- 230000023555 blood coagulation Effects 0.000 description 7
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 7
- 229960001008 heparin sodium Drugs 0.000 description 7
- 210000001772 blood platelet Anatomy 0.000 description 6
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 6
- 229960004408 lepirudin Drugs 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108010002156 Depsipeptides Proteins 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 208000001297 phlebitis Diseases 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000237678 Hirudinidae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- RVQDZELMXZRSSI-IUCAKERBSA-N Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 RVQDZELMXZRSSI-IUCAKERBSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000964941 Whitmania Species 0.000 description 1
- 241000258623 Whitmania pigra Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000006477 desulfuration reaction Methods 0.000 description 1
- 230000023556 desulfurization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001723 fibrinogenic effect Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000010581 sealed tube method Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Landscapes
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
The invention discloses a hirudin anticoagulation tube sealing device for a venous retention needle, which comprises a sleeve, a transparent tee joint connected with the rear end of the sleeve, and a transfusion connector connected with a transfusion tube or a blood collecting tube; a connecting part connected with a tube sealing injector is arranged on the middle section of an extension tube; the tube sealing injector comprises a liquid tube in which a tube cavity is formed, a needle part connected with the front end of a sealed tube, and a shell which is sleeved outside the liquid tube and of which the rear end is sealed; a raised clamping wire is formed on the outer surrounding wall of the rear end of the liquid tube; a clamping groove is formed on the inner surrounding wall of the front end of the shell, and clamping steps at equal distance intervals are formed on the inner surrounding wall of the shell; and a sealing plug connected with the rear wall of the shell is arranged in the liquid tube. The hirudin anticoagulation tube sealing device for the venous retention needle can ensure the same amount of tube sealing liquid can be pushed in at each time and the tube sealing liquid can fully fill the tube cavity of the retention needle. The tube sealing liquid in the tube sealing injector is dilute solution of hirudin which has high anticoagulation effect and does not influence the test of the indexes of the serum in blood.
Description
Technical field
The invention belongs to technical field of medical instruments, particularly relate to a kind of hirudin anticoagulant blood pipe sealing device of venous detaining needle.
Background technology
In recent years, develop rapidly, can alleviate the painful venous detaining needle of patient's repeated localised puncture and be widely used among critical patient's the patient of rescue transfusion, intravenous hyperalimentation and vein batch applications antibiotic or other medicines along with medical science applied.Venous detaining needle comprises puncture needle and sleeve pipe.After the puncture needle band sleeve pipe and penetrated patient's vein, extract puncture needle, sleeve pipe stays in the body, and the outer end connects infusion set or blood-taking device again.Venous detaining needle not only can be used for conventional venous transfusion, and can be used for repeatedly taking a blood sample discontinuously, and the misery of both having avoided repeated localised puncture to cause to the patient has been protected patient's vein again, can also improve nurse's work efficiency simultaneously.
Because the sleeve pipe of venous detaining needle needs the long period to stay in the human vein, after each transfusion is accomplished, cause tube chamber to stop up for preventing that blood from refluxing to condense, all need carry out tube sealing.Usually use common syringe that tube-sealing solution is injected now and carry out tube sealing in the remaining needle tube chamber." 2010 the 26th 1 phases of volume of practical Chinese medicine journal; Put down in writing in " application of venous detaining needle and nursing " literary composition that Zhang Jianrong, the Hou Sifang in the hospital of traditional Chinese hospital, Ninghe County, Tianjin delivers, the tube sealing maneuver is an important ring, adopts slowly injection malleation sealed-tube method usually; Be that the limit is slowly injected the limit and withdrawed from syringe needle; Guarantee that needle tip keeps malleation, avoid causing the blood coagulation plugging in backflow of blood to the blood vessel pin.Above-mentioned blood vessel pin promptly refers to the sleeve pipe of remaining needle.But this use ordinary syringe is carried out pipe sealing method, and to be the nurse push the dosage of tube-sealing solution according to oneself experience decision; The dosage control that does not have strict standard be difficult to guarantee all to be full of tube-sealing solution in each remaining needle tube chamber, and especially the sleeve pipe front end stretches into human body parts and is difficult to observe; If tube sealing does not thoroughly make backflow of blood to sleeve pipe front end; Caused the blood coagulation plugging not come to light again, agglomerative clot is poured in the human vein by liquid when infusing once more, can cause the generation of thrombosis.
" Chinese general family medicine " March in 2010, the 8th volume the 3rd phase 395-396 page or leaf was put down in writing heparin sodium diluent and normal saline that present clinical main tube-sealing solution commonly used is a variable concentrations in " effect of two kinds of tube sealing methods of venous detaining needle relatively ".Normal saline can prevent blood coagulation with the effect of keeping extracellular osmotic pressure, blood volume and water-electrolyte balance, blood circulation, and little to vascular stimulation, its malleation tube sealing is safe and reliable, and clinical practice is extensive than the heparin in sealing method.But the normal saline tube sealing time is shorter, and conventional normal saline needs 3-5 hour tube sealing once, has increased nurse's workload, also bothers patient and has a rest.And the normal saline tube sealing is prone to cause phlebitis; Because normal saline using dosage once probably needs 10-30ml; And generally can only tube sealing 3-5h, the nursing staff need be through normal saline flushing pipeline commonly used, and flushing line need puncture as the calparine cap of sealing end cap; Because calparine cap just is easy to by germ contamination through repeatedly puncturing, flows into human body through transfusion and cause symptoms such as phlebitis.Part calparine cap poor quality is arranged in addition, and repeatedly puncture is passed through infusion pipeline with trickle medical grade rubber chip easily, directly gets into human vas and causes bigger harm.
Therefore, clinically also often the result of use heparin sodium diluent that is superior to normal saline carry out tube sealing.Heparin is a kind of acid mucopolysaccharide; All has stronger anticoagulation when using in vivo and in vitro; The dilution back is widely used in clinical as the remaining needle tube-sealing solution; Use a small amount of Calciparine/sodium salt water sealing (sealing water) pipe, phlebitic incidence rate is starkly lower than the normal saline tube sealing, and tube sealing effect retention time is longer than the normal saline tube sealing.But the heparin sodium tube sealing still has inevitable shortcoming, because heparin sodium has certain side effect to cause anticoagulant easily, is prone to cause bleeding, dosage is difficult for shortcomings such as grasp; So for have, the patient of disturbances of blood coagulation; Ying Shenyong in order to avoid increase the weight of the state of an illness, adverse consequences occurs.The remaining needle operation of can drawing blood in addition avoids the patient by the misery of repeated localised puncture, but uses normal saline and the equal effect of heparin sodium undesirable.Normal saline is because using dosage is big, and dilute blood causes blood each item index on the low side easily, in addition because the characteristics of normal saline make too early the condensing of blood easily.The limitation of heparin sodium itself can't detect hematology's routine, whole blood test, hemorheology test, the experiment of projects such as serum biochemistry, pharmacokinetic experiment, serum biochemistry, blood bank's test, blood sugar test, erythrocyte sedimentation rate experiment fast with the blood that contains heparin sodium.The tube-sealing solution hirudin diluent that this utility model provides just can solve the disadvantage of above-mentioned two kinds of traditional tube-sealing solutions.
The People's Republic of China's " Chinese pharmacopoeia version in 2010; First one; The 57th page of record " Hirudo (HIRUDO) ", these article are the dry all of Hirudinidae animal whitmania Whitmania pigra Whitman, Hirudo Hirudo nipponica Whitman or Folium Salicis Babylonicae Hirudo Whitmania wranulata Whitman, and summer, Qiu Erji catch; Scald extremely with boiling water, dry or the low humidity drying.Concoct: Hirudo is cleaned, cutting, drying.Scald Hirudo: get water purification trematodiasis section, water to little with Pulvis Talci according to the method for scalding and heave.Function with cure mainly: removing blood stasis, removing blood stasis stimulates the menstrual flow.Be used for the blood stasis amenorrhea, injury from falling down.
Foreign medical science blood transfusion and 1993 the 16th volumes of blood fascicle the 6th phase record Chinese Academy of Medical Sciences Blood Research Institute, Guo Juan summary Wang Hebi examines and revises " progress of lepirudin 023 ludon " Haycraft and found in the Hementaria officianalis extract anticoagulant substances is arranged in 1884.At the end of the fifties, Markwardt isolates pure article first, called after hirudin (Hirudin), and know that it is the special inhibitor of thrombin, be a kind of ideal anticoagulant, antithrombotic preparation.Learn its structure and amino acid sequence the beginning of the eighties.Loaded down with trivial details because of the natural hirudin extraction step, and raise the Hirudo difficulty, the Hirudo source is deficient, is difficult to obtain the pure article of q.s, and research and clinical practice are restricted.In recent years; The development of technique for gene engineering has remedied this defective; Utilize chemosynthesis, cDNA library, PCR method to obtain gene clone, express obtaining lepirudin 023 ludon, thereby more in depth studied pharmacology, pharmacodynamics and the toxicity etc. of hirudin; A large amount of zooperies and clinic trial have been accelerated hirudin and have been applied to clinical process.
The structure of hirudin: natural hirudin is not contain polysaccharide, by the single chain protein that 65 or 66 amino acid residues are formed, and molecular weight about 7; 000, be rich in dicarboxylic amino acid, no Arg, Met and Trp; There are three intramolecular disulfide bonds to be positioned at peptide chain N-end, molecular configuration is played Stabilization; The C-end has more acidic amino acid residue, and a sulphation Tyr is arranged; The peptide chain middle part has one by Pro-Lys
47The special construction that-Pro forms, it plays certain function in hirudin and thrombin interaction.
In 11 kinds of variants of hirudin, only variant I, II and III have anticoagulating active.
So far, all can obtain active lepirudin 023 ludon through escherichia coli or Yeast system expression, and be desulfurization acidic group hirudin, promptly 63 Tyr do not have sulphation.Reorganization has isomorphic map mutually with natural prodcuts.Further can produce multiple variant.
Along with the molecular biology develop rapidly, external at present existing tens companies develop lepirudin 023 ludon and the plain preparation of functional Hirudo, and a large amount of tests show that recombinant products is similar with natural prodcuts, are effective anticoagulant and antithrombotic preparation.
The clinical indication of lepirudin 023 ludon can be summarized as follows: 1) surgery anticoagulant; 2) internal medicine anticoagulant; 3) adjuvant of thrombolytic drug; 4) anticoagulant of angioplasty; 5) anticoagulant etc. in the hemodialysis.On the experimentation basis, carrying out clinical bulge test (like subacute and chronic DIC) at present.
The architectural feature of hirudin:
The single chain protein that natural hirudin is made up of 65 amino acid residues, the about 7000D of molecular weight is rich in dicarboxylic amino acid, no Arg, Met, Trp, peptide chain N-end has 3 intramolecular disulfide bond (Cys6-Cys14; Cys16-Cys28; Cys22-Cys39), molecular configuration is played Stabilization.The C-end has more acidic amino acid residue, and a sulphation Tyr is arranged, and is worked in the interaction of hirudin and thrombin by the special construction that a Pro-Lys47-Pro forms in the peptide chain middle part.
The chemical constitution of hirudin:
Hirudin on sale at present in market.
Summary of the invention
The present invention provides a kind of tube sealing effect that can guarantee in order to solve the variety of issue that exists in the prior art, does not influence the hirudin anticoagulant blood pipe sealing device of the venous detaining needle of blood parameters again.
The technical scheme that the present invention takes for the technical problem that exists in the solution known technology is:
The hirudin anticoagulant blood pipe sealing device of venous detaining needle of the present invention comprises by the puncture needle guiding penetrating intravenous sleeve pipe, is connected the transparent threeway and the infusion connector that is used to be connected infusion pipeline or blood sampling pipeline of the built-in isolating seal plug of sleeve pipe rear end; One end of transparent threeway and telescopic joint, an end is sealed by the isolating seal plug, and the 3rd end is connected with infusion connector through prolonging pipe, and infusion connector is by the sealing end caps; The stage casing that prolongs pipe is provided with the connecting portion that connects the tube sealing syringe, connecting portion and prolongation pipe internal communication; The tube sealing syringe comprises the inner liquid storage pipe that forms tube chamber, is connected the syringe needle part of liquid storage pipe front end and is socketed in outside the liquid storage pipe and the shell of back-end closure; Be formed with protruding clamping line on the periphery wall of liquid storage pipe rear end; Be formed with on the internal perisporium of shell front end with liquid storage pipe on the draw-in groove that is connected of clamping line, be formed with the card rank of same distance at interval on the shell internal perisporium; Be provided with the sealing-plug that is connected with housing back wall in the liquid storage pipe.Card rank on the described shell internal perisporium are anterior recessed, the inclined-plane of rear portion protrusion.
The syringe needle part of described tube sealing syringe is connected with the connecting portion on prolonging pipe, and integrally formed with the perisporium of connecting portion; A side that perhaps prolongs the connecting portion on the pipe is formed with the insertion section of opening by the seal head sealing; The draw point of tube sealing syringe needle head part front end passes seal head and inserts in the connecting portion.
The tube-sealing solution of splendid attire is the hirudin diluent in the described liquid storage pipe.
The concentration of hirudin is 0.01mg/ml-50mg/ml in the described hirudin diluent.Preferred 0.01mg/ml-40mg/ml uses according to the about 1ml-15ml of different needs at every turn.
Described sleeve pipe adopts four polyvinyl fluoride materials to process; Transparent threeway adopts medical material polythene material to process with the infusion connector that is used to be connected infusion pipeline or take a blood sample pipeline; The puncture needle material is that medical stainless steel is processed; Isolating seal plug, sealing-plug are that medical butyl rubber plug is processed, the sealing end cap, draw-in groove, shell, card rank, clamping line, connector, liquid stopping block, hold needle handle, the puncture needle handle be that medical plastic is processed, liquid storage pipe is processed for the medical high polymer plastics.
Another kind of embodiment of the present invention is: a kind of hirudin anticoagulant blood pipe sealing device of venous detaining needle; Comprise by the puncture needle guiding penetrating intravenous sleeve pipe, be connected the transparent threeway and the infusion connector that is used to be connected infusion pipeline or blood sampling pipeline of the built-in isolating seal plug of sleeve pipe rear end; One end of transparent threeway and telescopic joint, an end is sealed by the isolating seal plug, and the 3rd end is connected with infusion connector through prolonging pipe, and infusion connector is by the sealing end caps; The stage casing that prolongs pipe is provided with the connecting portion that connects the tube sealing syringe, connecting portion and prolongation pipe internal communication; The tube sealing syringe comprises the inner liquid storage pipe that forms tube chamber, is connected the syringe needle part and the shell that is connected in the liquid storage pipe of liquid storage pipe front end; Be formed with protruding clamping line on the periphery wall of shell front end; Be formed with on the internal perisporium of liquid storage pipe rear end with shell on the draw-in groove that is connected of clamping line, be formed with the card rank of same distance at interval on the liquid storage pipe internal perisporium; Be provided with the sealing-plug that is connected with housing back wall in the liquid storage pipe.Card rank on the described liquid storage pipe internal perisporium are anterior protrusion, the inclined-plane that the rear portion is recessed.
The syringe needle part of described tube sealing syringe is connected with the connecting portion on prolonging pipe, and integrally formed with the perisporium of connecting portion; A side that perhaps prolongs the connecting portion on the pipe is formed with the insertion section of opening by the seal head sealing; The draw point of tube sealing syringe needle head part front end passes seal head and inserts in the connecting portion.
The tube-sealing solution of splendid attire is the hirudin diluent in the described liquid storage pipe.
The concentration of hirudin is 0.01mg/ml-50mg/ml in the described hirudin diluent.Preferred 0.01mg/ml-40mg/ml uses according to the about 1ml-15ml of different needs at every turn.
Described sleeve pipe adopts four polyvinyl fluoride materials to process; Transparent threeway adopts medical material polythene material to process with the infusion connector that is used to be connected infusion pipeline or take a blood sample pipeline; The puncture needle material is that medical stainless steel is processed; Isolating seal plug, sealing-plug are that medical butyl rubber plug is processed, the sealing end cap, draw-in groove, shell, card rank, clamping line, connector, liquid stopping block, hold needle handle, the puncture needle handle be that medical plastic is processed, liquid storage pipe is processed for the medical high polymer plastics.
Advantage and good effect that the present invention has are:
The hirudin anticoagulant blood pipe sealing device of venous detaining needle of the present invention connects the tube sealing syringe on venous detaining needle, and the interval same distance is provided with the card rank on the outer casing inner wall of tube sealing syringe; When promoting shell; When the clamping line on the liquid storage pipe runs into the card rank, receive certain resistance and stop relative motion, at this moment; Stop to promote shell, guarantee to push the tube-sealing solution of same dose at every turn.Distance between the card rank can guarantee that through calculating tube-sealing solution is full of the tube chamber of remaining needle, avoids backflow of blood and the blood coagulation plugging.Anticoagulant in the tube sealing syringe is selected the hirudin diluent for use, compares with other tube-sealing solution, and hirudin had both had good anticoagulation, can not influence the detection of anticoagulin in the blood again, suits repeatedly be used for tube sealing in discontinuity transfusion and the blood collection procedure.
Description of drawings
Fig. 1 is the structural representation of hirudin anticoagulant blood pipe sealing device of the venous detaining needle of first embodiment of the invention;
Fig. 2 is the structural representation of the venous detaining needle of second embodiment of the invention;
Fig. 3 is the structural representation of the tube sealing syringe of second embodiment of the invention.
Critical piece symbol description in the accompanying drawing:
1: sleeve pipe 2: transparent threeway 3: isolating seal plug
4: prolong pipe 5: liquid stopping block 6: infusion connector
7: the first sealing end caps sealing in 8: the second end cap 9: syringe needle part
10: sealing-plug 11: connecting portion 12: liquid storage pipe
13: draw-in groove 14: shell 15: the card rank
16: clamping line 17: puncture needle 18: the puncture needle handle
19: hold needle handle 20: tube sealing syringe 21: connector
22: insertion section 23: seal head.
The specific embodiment
Followingly the present invention is carried out detailed explanation with reference to accompanying drawing and embodiment.The parts identical with prior art have used identical symbol among the present invention.
Fig. 1 is the structural representation of hirudin anticoagulant blood pipe sealing device of the venous detaining needle of first embodiment of the invention.As shown in Figure 1; The hirudin anticoagulant blood pipe sealing device of the venous detaining needle of first embodiment; Comprise by the puncture needle guiding penetrating intravenous sleeve pipe 1, be connected the transparent threeway 2 and the infusion connector 6 that is used to be connected infusion pipeline or blood sampling pipeline of the built-in isolating seal plug 3 of sleeve pipe 1 rear end.
One end of transparent threeway 2 is connected with sleeve pipe 1, and an end is sealed by isolating seal plug 3, and the 3rd end is connected with infusion connector 6 through prolonging pipe 4.Prolong pipe 4 and be provided with liquid stopping block 5.Sleeve pipe 1 is socketed in outside the puncture needle 17, and stretch out from the front end of sleeve pipe 1 at the tip of puncture needle 17.The rear end of puncture needle 17 is provided with puncture needle handle 18, after sleeve pipe 1 gets into vein for ease, puncture needle 17 is extracted, and a side of puncture needle handle 18 is provided with holds needle handle 19.
The stage casing that prolongs pipe 4 is provided with the connecting portion 11 that connects tube sealing syringe 20, connecting portion 11 and prolongation pipe 4 internal communication.Tube sealing syringe 20 comprises the inner liquid storage pipe 12 that forms tube chamber, is connected the syringe needle part 9 of liquid storage pipe 12 front ends and is socketed in outside the liquid storage pipe and the shell 14 of back-end closure.Be formed with protruding clamping line 16 on the periphery wall of liquid storage pipe 12 rear ends.Be formed with on the internal perisporium of shell 14 front ends with liquid storage pipe 12 on the draw-in groove 13 that is connected of clamping line 16, be formed with the card rank 15 of same distance at interval on shell 14 internal perisporiums.Card rank 15 are anterior recessed, the inclined-plane of rear portion protrusion.The central authorities of shell 14 rear walls are formed with and extend to liquid storage pipe 12 intraluminal connectors 21, are fixedly connected on the front end of connector 21 with the sealing-plug 10 that liquid storage pipe 12 inwalls closely contact.
The syringe needle part 9 of tube sealing syringe 20 is connected with the connecting portion 11 that prolongation is managed on 4, and integrally formed with the perisporium of connecting portion 11.
The tube-sealing solution of splendid attire is the hirudin diluent of 0.01mg/ml in the above-mentioned liquid storage pipe 12.
Embodiment 2
Fig. 2 is the structural representation of the venous detaining needle of second embodiment of the invention; Fig. 3 is the structural representation of the tube sealing syringe of second embodiment of the invention.As shown in Figures 2 and 3; The hirudin anticoagulant blood pipe sealing device of the second embodiment venous detaining needle; Comprise by puncture needle 17 guiding penetrating intravenous sleeve pipe 1, be connected the transparent threeway 2 and the infusion connector 6 that is used to be connected infusion pipeline or blood sampling pipeline of the built-in isolating seal plug 3 of sleeve pipe 1 rear end.
One end of transparent threeway 2 is connected with sleeve pipe 1, and an end is sealed by isolating seal plug 3, and the 3rd end is connected with infusion connector 6 through prolonging pipe 4.Prolong pipe 4 and be provided with liquid stopping block 5.Sleeve pipe 1 is socketed in outside the puncture needle 17, and stretch out from the front end of sleeve pipe 1 at the tip of puncture needle 17.The rear end of puncture needle 17 is provided with puncture needle handle 18, after sleeve pipe 1 gets into vein for ease, puncture needle 17 is extracted, and a side of puncture needle handle 18 is provided with holds needle handle 19.
The stage casing that prolongs pipe 4 is provided with the connecting portion 11 that connects tube sealing syringe 20, connecting portion 11 and prolongation pipe 4 internal communication.One side of connecting portion 11 is formed with the insertion section 22 of opening by seal head 23 sealings.Tube sealing syringe 20 comprises the inner liquid storage pipe 12 that forms tube chamber, is connected the syringe needle part 9 of liquid storage pipe 12 front ends and is socketed in outside the liquid storage pipe 12 and the shell 14 of back-end closure.The draw point of tube sealing syringe needle head part 9 front ends passes seal head 23 and inserts in the connecting portion 11.Be formed with protruding clamping line 16 on the periphery wall of liquid storage pipe 12 rear ends.Be formed with on the internal perisporium of shell front end with liquid storage pipe on the draw-in groove 13 that is connected of clamping line 16, be formed with the card rank 15 of same distance at interval on the shell internal perisporium, card rank 15 be anterior recessed, the inclined-plane that protrude at the rear portion.。Be provided with in the liquid storage pipe 12 and the sealing-plug 10 that closely contacts with the liquid storage pipe inwall.The central authorities of shell 14 rear walls are formed with and extend to liquid storage pipe 12 intraluminal connectors 21; Sealing-plug 10 is fixedly connected on the front end of connector 21.
The tube-sealing solution of splendid attire is the hirudin diluent of 1mg/ml in the above-mentioned liquid storage pipe 12.
Each transfusion finishes or blood sampling when accomplishing, and tube sealing syringe 20 is inserted in connecting portions 11 tube chambers by seal head 23, push a certain amount of tube-sealing solution after, tube sealing syringe 20 is extracted preservation.
The hirudin anticoagulant blood pipe sealing device of the venous detaining needle of third embodiment of the invention; Comprise by the puncture needle guiding penetrating intravenous sleeve pipe, be connected the transparent threeway and the infusion connector that is used to be connected infusion pipeline or blood sampling pipeline of the built-in isolating seal plug of sleeve pipe rear end.
One end of transparent threeway and telescopic joint, an end is sealed by the isolating seal plug, and the 3rd end is connected with infusion connector through prolonging pipe.Infusion connector can adopt single lumen catheter, also can adopt double lumen tube.If the employing single lumen catheter, the free end of single lumen catheter is by the sealing end caps; If the employing double lumen tube, two kinds of different drug of infusion simultaneously, the two ends of double lumen tube are respectively by the first sealing end cap and the second sealing end caps.
The stage casing that prolongs pipe is provided with the connecting portion that connects the tube sealing syringe, connecting portion and prolongation pipe internal communication.The tube sealing syringe comprises the inner liquid storage pipe that forms tube chamber, is connected the syringe needle part and the shell that is connected in the liquid storage pipe of liquid storage pipe front end.Be formed with protruding clamping line on the periphery wall of shell front end.Be formed with on the internal perisporium of liquid storage pipe rear end with shell on the draw-in groove that is connected of clamping line, be formed with the card rank of same distance at interval on the liquid storage pipe internal perisporium, the card rank be anteriorly to protrude the inclined-plane that the rear portion is recessed.Be provided with the sealing-plug that is connected with housing back wall in the liquid storage pipe.The central authorities of housing back wall are formed with and extend to the intraluminal connector of liquid storage pipe; Sealing-plug is fixedly connected on the front end of connector.
The syringe needle part of tube sealing syringe is connected with the connecting portion on prolonging pipe, and integrally formed with the perisporium of connecting portion.
Sleeve pipe adopts four polyvinyl fluoride materials to process; Transparent threeway adopts medical material polythene material to process with the infusion connector that is used to be connected infusion pipeline or take a blood sample pipeline; The puncture needle material is that medical stainless steel is processed; Isolating seal plug, sealing-plug are that medical butyl rubber plug is processed, the sealing end cap, draw-in groove, shell, card rank, clamping line, connector, liquid stopping block, hold needle handle, the puncture needle handle be that medical plastic is processed, liquid storage pipe is processed for the medical high polymer plastics.
The tube-sealing solution of splendid attire is the hirudin diluent of 3mg/ml in the above-mentioned liquid storage pipe.
Embodiment 4
The hirudin anticoagulant blood pipe sealing device of the venous detaining needle of fourth embodiment of the invention; Comprise by the puncture needle guiding penetrating intravenous sleeve pipe, be connected the transparent threeway and the infusion connector that is used to be connected infusion pipeline or blood sampling pipeline of the built-in isolating seal plug of sleeve pipe rear end.
One end of transparent threeway and telescopic joint, an end is sealed by the isolating seal plug, and the 3rd end is connected with infusion connector through prolonging pipe.Casing pipe sleeve is connected on outside the puncture needle, and stretch out from telescopic front end at the tip of puncture needle.The rear end of puncture needle is provided with the puncture needle handle, after sleeve pipe gets into vein for ease, puncture needle is extracted, and a side of puncture needle handle is provided with holds needle handle.
Infusion connector can adopt single lumen catheter, also can adopt double lumen tube.If the employing single lumen catheter, the free end of single lumen catheter is by the sealing end caps; If the employing double lumen tube, two kinds of different drug of infusion simultaneously, the two ends of double lumen tube are respectively by the first sealing end cap and the second sealing end caps.
The stage casing that prolongs pipe is provided with the connecting portion that connects the tube sealing syringe, connecting portion and prolongation pipe internal communication.One side of connecting portion is formed with the insertion section of opening by the seal head sealing.The tube sealing syringe comprises the inner liquid storage pipe that forms tube chamber, is connected the syringe needle part and the shell that is connected in the liquid storage pipe of liquid storage pipe front end.The draw point of tube sealing syringe needle head part front end passes seal head and inserts in the connecting portion.Be formed with protruding clamping line on the periphery wall of shell front end.Be formed with on the internal perisporium of liquid storage pipe rear end with shell on the draw-in groove that is connected of clamping line, be formed with the card rank of same distance at interval on the liquid storage pipe internal perisporium, the card rank be anteriorly to protrude the inclined-plane that the rear portion is recessed.Be provided with the sealing-plug that is connected with housing back wall in the liquid storage pipe.The central authorities of housing back wall are formed with and extend to the intraluminal connector of liquid storage pipe; Sealing-plug is fixedly connected on the front end of connector.
Sleeve pipe adopts four polyvinyl fluoride materials to process; Transparent threeway adopts medical material polythene material to process with the infusion connector that is used to be connected infusion pipeline or take a blood sample pipeline; The puncture needle material is that medical stainless steel is processed; Isolating seal plug, sealing-plug are that medical butyl rubber plug is processed, the sealing end cap, draw-in groove, shell, card rank, clamping line, connector, liquid stopping block, hold needle handle, the puncture needle handle be that medical plastic is processed, liquid storage pipe is processed for the medical high polymer plastics.
The tube-sealing solution of splendid attire is the hirudin diluent of 8mg/ml in the above-mentioned liquid storage pipe.
Each transfusion finishes or blood sampling when accomplishing, and the tube sealing syringe is inserted in the connecting portion tube chamber by seal head, push a certain amount of tube-sealing solution after, the tube sealing syringe is extracted preservation.
According to first embodiment and second embodiment, specify and use tube sealing syringe of the present invention to carry out pipe sealing method: when the tube sealing syringe was not used, the clamping line of liquid storage pipe was positioned at the draw-in groove of shell front end below.When using for the first time, promote the rear wall of shell forward with uniform power, sealing-plug moves forward, in the tube chamber of tube-sealing solution by syringe needle inflow remaining needle.The clamping line is deviate from draw-in groove, moves backward with respect to shell, when meeting first card rank, runs into certain resistance.Liquid storage pipe and shell stop relative motion, at this moment, stop thrust, and the tube-sealing solution in the liquid storage pipe is no longer flowed out by the syringe needle place, accomplishes No. one time tube sealing.Forward promote shell during tube sealing next time again, and the clamping line moves to second Ka Jiechu by first Ka Jiechu, accomplishes tube sealing again No. one time, by that analogy.Per two card rank spacing distances equate, guarantee to push the tube-sealing solution of same dose at every turn.Distance between the card rank can guarantee that through calculating tube-sealing solution is full of the tube chamber of remaining needle, avoids backflow of blood and the blood coagulation plugging.
Comparative experiments
Hirudin concentration is: 0.01mg/ml～10mg/ml uses according to the about 1ml-15ml of different needs at every turn.
The relation of hirudin and thrombin is following:
The first, lepirudin 023 ludon and α-thrombin with etc. mole non-covalent combine to form stabilized complex (its dissociation constant is very little, 0.8 * 10
-10Mol or 2.0 * 10
-14Mol).The whole protease hydrolysis functions of thrombin this moment are closed; So hirudin can not only prevent fibrinogenic consolidation; And can block the hemostasis reaction of catalyzed by thrombin, such as the platelet response that activation and the thrombin of factor V, VIII and III brings out, prevented the activatory feedback of thrombinogen and the thrombin that causes generates; Hirudin does not disturb the biosynthesis of thrombin simultaneously, and (AT-III) also do not have influence to Antithrombin III.
The second, oxidized when hirudin, disulfide bond, or its C-end is shown that by depsipeptides (the C-end reduces by 7 or 22 aminoacid then to the inhibition loss of activity 90% or 100% of thrombin) hirudin is a reversibility to the inhibitory action of thrombin.
Hirudin has following characteristics in practical application:
The first, the agent of gene recombinaton hirudin anticoagulant does not contain heavy metal ion, does not have Sulfated pure biological preparation, and is noiseless to test item, is applicable to detections such as biochemistry, immunology, hematology.Also be applicable to unit blood specimen collections such as medical research mechanism, blood station, health and epidemic prevention.
The second, the Tyr peptide chain structure of hirudin can suppress the thrombin specificity, but this effect is reversible, and when the reaction of Tyr peptide chain warp depsipeptides, after the hirudin forfeiture suppressed activity, blood preparation also can be done hemagglutination test again.
The 3rd, haemachrome hematocrit and leukocyte etc. all there are not influence, can not only be used for the research of Physiological Experiment and clotting mechanism, and on clinical medicine, also can be used as the anticoagulant when transfusing blood.
The 4th, can reduce surface activity of blood platelet to platelet, anticoagulant reduces platelet adhesion property.Hirudin can suppress the adhesive attraction of platelet to silication glass, and this is not direct interaction to hematoblastic effect, and it does not disturb hematoblastic function.
The 5th; The blood coagulation resisting function of hirudin in different animals and blood plasma its anticoagulation that confirms different with heparin; It does not rely on anticoagulant factor, does not disturb the detection of anticoagulant factor yet, does not receive influence of platelet CA++ (PF4) and rich histidine protein or the like yet.It is the safest, the most effective natural antithrombase anticoagulant in the known anticoagulative substance in the present world.
Claims (9)
1. the hirudin anticoagulant blood pipe sealing device of a venous detaining needle; Comprise by the puncture needle guiding penetrating intravenous sleeve pipe (1), be connected the transparent threeway (2) and the infusion connector (6) that is used to be connected infusion pipeline or blood sampling pipeline of the built-in isolating seal plug (3) of sleeve pipe rear end; One end of transparent threeway (2) and telescopic joint, an end is sealed by isolating seal plug (3), and the 3rd end is connected with infusion connector (6) through prolonging pipe (4), and infusion connector is by the sealing end caps; It is characterized in that: the stage casing that prolongs pipe (4) is provided with the connecting portion (11) that connects tube sealing syringe (20), connecting portion (11) and prolongation pipe internal communication; Tube sealing syringe (20) comprises the inner liquid storage pipe (12) that forms tube chamber, is connected the syringe needle part (9) of liquid storage pipe front end and is socketed in outside the liquid storage pipe and the shell (14) of back-end closure; Be formed with protruding clamping line (16) on the periphery wall of liquid storage pipe (12) rear end; Be formed with on the internal perisporium of shell (14) front end with liquid storage pipe on the draw-in groove (13) that is connected of clamping line, be formed with the card rank (15) of same distance at interval on shell (14) internal perisporium; Be provided with the sealing-plug (10) that is connected with shell (14) rear wall in the liquid storage pipe (12).
2. the hirudin anticoagulant blood pipe sealing device of a venous detaining needle comprises by the puncture needle guiding penetrating intravenous sleeve pipe, is connected the transparent threeway and the infusion connector that is used to be connected infusion pipeline or blood sampling pipeline of the built-in isolating seal plug of sleeve pipe rear end; One end of transparent threeway and telescopic joint, an end is sealed by the isolating seal plug, and the 3rd end is connected with infusion connector through prolonging pipe, and infusion connector is by the sealing end caps; It is characterized in that: the stage casing that prolongs pipe is provided with the connecting portion that connects the tube sealing syringe, connecting portion and prolongation pipe internal communication; The tube sealing syringe comprises the inner liquid storage pipe that forms tube chamber, is connected the syringe needle part and the shell that is connected in the liquid storage pipe of liquid storage pipe front end; Be formed with protruding clamping line on the periphery wall of shell front end; Be formed with on the internal perisporium of liquid storage pipe rear end with shell on the draw-in groove that is connected of clamping line, be formed with the card rank of same distance at interval on the liquid storage pipe internal perisporium; Be provided with the sealing-plug that is connected with housing back wall in the liquid storage pipe.
3. according to the hirudin anticoagulant blood pipe sealing device of claim 1 or the described venous detaining needle of claim 2; It is characterized in that: the syringe needle part (9) of tube sealing syringe (20) is connected with the connecting portion (11) that prolongs on managing, and integrally formed with the perisporium of connecting portion (11).
4. according to the hirudin anticoagulant blood pipe sealing device of claim 1 or the described venous detaining needle of claim 2, it is characterized in that: a side that prolongs the connecting portion (11) on the pipe is formed with the insertion section (22) of opening by seal head (23) sealing; The draw point of tube sealing syringe needle head part (9) front end passes seal head (23) and inserts in the connecting portion (11).
5. the hirudin anticoagulant blood pipe sealing device of venous detaining needle according to claim 1 is characterized in that: the card rank on the shell internal perisporium are for anterior recessed, the inclined-plane of rear portion protrusion.
6. the hirudin anticoagulant blood pipe sealing device of venous detaining needle according to claim 2 is characterized in that: the card rank on the liquid storage pipe internal perisporium are anterior protrusion, the inclined-plane that the rear portion is recessed.
7. according to the hirudin anticoagulant blood pipe sealing device of claim 1 or the described venous detaining needle of claim 2, it is characterized in that: the tube-sealing solution of splendid attire is the hirudin diluent in the liquid storage pipe.
8. the hirudin anticoagulant blood pipe sealing device of venous detaining needle according to claim 7, it is characterized in that: the concentration of hirudin is 0.01mg/ml-50mg/ml in the hirudin diluent.
9. according to the hirudin anticoagulant blood pipe sealing device of claim 1 or the described venous detaining needle of claim 2; It is characterized in that: sleeve pipe (1) adopts four polyvinyl fluoride materials to process; Transparent threeway (2) adopts medical material polythene material to process with the infusion connector (6) that is used to be connected infusion pipeline or to take a blood sample pipeline; Puncture needle (17) adopts medical stainless steel to process; Isolating seal plug (3), sealing-plug (10) are processed for medical butyl rubber plug, and sealing end cap (7,8), draw-in groove (13), shell (14), card rank (15), clamping line (16) are processed for medical plastic, and liquid storage pipe is processed for the medical high polymer plastics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100272229A CN102120051B (en) | 2011-01-26 | 2011-01-26 | Hirudin anticoagulation tube sealing device for venous retention needle |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100272229A CN102120051B (en) | 2011-01-26 | 2011-01-26 | Hirudin anticoagulation tube sealing device for venous retention needle |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102120051A CN102120051A (en) | 2011-07-13 |
| CN102120051B true CN102120051B (en) | 2012-01-18 |
Family
ID=44248777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100272229A Expired - Fee Related CN102120051B (en) | 2011-01-26 | 2011-01-26 | Hirudin anticoagulation tube sealing device for venous retention needle |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102120051B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103330965B (en) * | 2013-03-25 | 2015-08-05 | 南通恒泰医疗器材有限公司 | A kind of single use periphery cannula infusion device |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6146358A (en) * | 1989-03-14 | 2000-11-14 | Cordis Corporation | Method and apparatus for delivery of therapeutic agent |
| WO2000072906A1 (en) * | 1999-06-01 | 2000-12-07 | Becton, Dickinson And Company | Kit for flushing medical devices and method of preparing the flushing solution |
| EP1340458A1 (en) * | 2002-02-28 | 2003-09-03 | Becton, Dickinson and Company | Shieldable fluid collection set |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101879341A (en) * | 2010-06-24 | 2010-11-10 | 张亚平 | Safety venous indwelling needle with needleless interface positive-pressure closing valve |
-
2011
- 2011-01-26 CN CN2011100272229A patent/CN102120051B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6146358A (en) * | 1989-03-14 | 2000-11-14 | Cordis Corporation | Method and apparatus for delivery of therapeutic agent |
| WO2000072906A1 (en) * | 1999-06-01 | 2000-12-07 | Becton, Dickinson And Company | Kit for flushing medical devices and method of preparing the flushing solution |
| EP1340458A1 (en) * | 2002-02-28 | 2003-09-03 | Becton, Dickinson and Company | Shieldable fluid collection set |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102120051A (en) | 2011-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102068731B (en) | Venous retention needle suite with hirudin anticoagulation tube sealing device | |
| CN202185013U (en) | Anti-coagulation sealing tube suite | |
| CN102068730B (en) | Hirudin anticoagulation seal tube kit for vein detained needle | |
| CN202028026U (en) | Venous remaining needle with pipe sealing device | |
| CN101695446B (en) | Disposable soft connecting band collection container and anti-freezing vacuum blood taking needle of bleeding opening | |
| CN201939797U (en) | Pipe-sealing device for intravenous indwelling needle | |
| CN202376556U (en) | Anticoagulant tube sealer for vein remaining needle | |
| CN102120051B (en) | Hirudin anticoagulation tube sealing device for venous retention needle | |
| CN202027990U (en) | Venous retention needle sleeve element with pipe sealing device | |
| CN201996922U (en) | Intravenous indwelling needle tube sealing assembly | |
| CN101695447B (en) | Disposable hard connecting band collection container and anti-freezing vacuum blood taking needle of bleeding opening | |
| CN102119861B (en) | Venous indwelling needle with hirudin anticoagulation pipe-sealing device | |
| CN102488939A (en) | Anticoagulation pipe sealing device of venous indwelling needle | |
| CN102038986A (en) | Vein remaining needle | |
| CN201631207U (en) | Disposable hard-connected parallel multi-tube anticoagulant vacuum blood sampling matched set | |
| CN201516035U (en) | Anti-coagulation vacuum blood collecting needle of disposable soft tape splicing collecting container | |
| CN104826196A (en) | Self-sealing type venous indwelling needle with liquid bag in needle holder | |
| CN201519153U (en) | Disposable hard-wired type anti-coagulation blood taking needle | |
| CN205339731U (en) | Interior liquid bag of needle file is proclaimed oneself formula vein and is kept somewhere needle | |
| CN201524083U (en) | Disposable flexibly connected anticoagulant blood taking needle | |
| CN2820201Y (en) | Closed polyester venous retaining needle | |
| CN201516037U (en) | Anti-coagulation vacuum blood collecting needle of disposable hard tape splicing collecting container | |
| CN201516034U (en) | Anti-coagulation vacuum blood collecting needle of disposable hard connecting belt blood specimen collecting container | |
| CN101785677B (en) | Disposable hard connection hirudin anti-coagulation transverse vacuum blood collection kit | |
| CN101785676B (en) | Disposable flexible connection hirudin anti-coagulation transverse vacuum blood collection kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20160817 Granted publication date: 20120118 |
|
| RINS | Preservation of patent right or utility model and its discharge | ||
| PD01 | Discharge of preservation of patent | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20170607 Granted publication date: 20120118 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170629 Address after: Tianjin Development Zone 300450 Fifth Avenue Taihua Road No. 12 TEDA SME development center room 3024 Patentee after: Tianjin hundred new biotechnology research and Development Co.,Ltd. Address before: 300384 Tianjin Huayuan Industrial Park Torch Hotel 501 Patentee before: TIANJIN BAILIKANGTAI BIOTECH Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120118 Termination date: 20220126 |